Core Viewpoint - Envoy Medical, Inc. has announced the issuance of four new patents related to innovative hearing solutions, emphasizing its commitment to advancing technology in the hearing health industry [1][2][3][4][5]. Patent Announcements - The US Patent & Trademark Office issued US Patent No. 12,151,102 for a Combination Hearing Aid and Cochlear Implant System, focusing on updating transfer functions in cochlear implants to accommodate external hearing aids [2]. - The European Patent Office will grant European Patent No. 4255554, also for a Combination Hearing Aid and Cochlear Implant System, which includes a status indicator for external auditory devices [3]. - European Patent No. 4255555 will be granted for Cochlear Implant Stimulation Calibration, which involves calibrating current flow in cochlear implant systems [4]. - European Patent No. 4319866 will be granted for Cochlear Implant System with Electrode Impedance Diagnostics, allowing for the determination of impedance and stimulation parameters in cochlear implants [5]. Product Innovations - The Acclaim Cochlear Implant is highlighted as a first-of-its-kind fully implanted device designed to address severe to profound sensorineural hearing loss, leveraging the natural anatomy of the ear [6][7]. - The Acclaim CI received Breakthrough Device Designation from the FDA in 2019, indicating its potential significance in the market [7]. - The Esteem Fully Implanted Active Middle Ear Implant (FI-AMEI) is noted as the only FDA-approved fully implanted hearing device for adults with moderate to severe sensorineural hearing loss, providing continuous hearing without external components [9].
Envoy Medical Receives Additional Patent Protection for its Innovative Approach to Hearing Loss